• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Seqirus to highlight new data in seasonal influenza prevention at Options IX for the Control of Influenza conference

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

- Two poster presentations reinforce the safety of MF59®-adjuvanted seasonal trivalent influenza vaccine in adults 65 years of age and older in addition to demonstrating increased breadth of antibody responses[1,2]

- Quadrivalent inactivated influenza vaccine data demonstrates safety and immunogenicity in children aged 5 to 17 and adults aged 18 years and older[3,4]

- Total of seven poster presentations and a symposium underscore Seqirus' commitment to prevention and control of seasonal influenza


News provided by

Seqirus

Aug 24, 2016, 04:37 ET

Share this article

Share this article


MAIDENHEAD, United Kingdom, Aug. 24, 2016 /PRNewswire/ -- Seqirus announced today that seven poster presentations reporting results of the company's research and development in seasonal influenza prevention and control have been accepted at the Options IX for the Control of Influenza conference (Options IX) in Chicago, 24-28 August 2016.

Presentations include data evaluating MF59®-adjuvanted seasonal trivalent influenza vaccine in adults aged 65 years and older, MF59, quadrivalent inactivated influenza vaccine in people aged 5 years and older, and Rapivab® (peramivir injection), an antiviral drug. Seqirus will also be hosting "Dissecting the Influenza Challenge: Perspectives on Prevention and Management," a symposium led by:

  • Symposium Chair – Dr. Arnold Monto, MD, Professor, Epidemiology, University of Michigan
  • Symposium Faculty – Dr. Nelson Lee, MD, Head and Professor of Infectious Diseases, The Chinese University of Hong Kong, Honorary Consultant of the Hospital Authority of Hong Kong; Chairman of Infectious Diseases Board
  • Symposium Faculty – Dr. Paul Van Buynder, MBBS, MPH, Public Health Physician, Gold Coast Health Service

"The wealth of scientific knowledge presented at this year's Options IX conference underscores our commitment to the prevention and control of seasonal influenza," said Russell Basser, MD, Senior Vice President, Research & Development, Seqirus. "Seqirus is proud to offer one of the broadest portfolios of influenza vaccines this season, delivering on our promise to help improve public health around the world."

Data being presented across areas of focus for Seqirus include:

  • MF59-Adjuvanted Seasonal Trivalent Influenza Vaccine: Pooled Analysis of Safety in Adults 65 Years of Age or Older (Abstract # P-368, 26 August, 7:00 am – 7:30 pm CDT)[1]
  • Heterologous Antibody Responses to MF59-Adjuvanted A/H5n1 Pandemic Vaccine in Adults, Pediatric and Elderly Populations (Abstract # P-363, 26 August, 7:00 am – 7:30 pm CDT)[5]
  • Antibody Responses Against Antigenically Drifted Strains of FLUAD, a Seasonal MF59-Adjuvanted Trivalent Influenza Vaccine in Older Adults (Abstract # P-360, 26 August, 7:00 am – 7:30 pm CDT)[2]
  • Health Economics for Seasonal Influenza Vaccination of Older Adults in Italy (Abstract # P-372, 26 August, 7:00 am – 7:30 pm CDT)[6]
  • Randomized Trial to Compare Immunogenicity and Safety of Seqirus Quadrivalent Inactivated Influenza Vaccine with a US-Licensed Quadrivalent Influenza Vaccine in Children 5 to 17 Years of Age (Abstract # P-286, 26 August, 7:00 am – 7:30 pm CDT)[3]
  • Randomized Trial to Compare Immunogenicity and Safety of Seqirus Quadrivalent Inactivated Influenza Vaccine with Two Trivalent Influenza Vaccine Comparators in Adults Aged 18 Years and Above (Abstract # P-498 Number, 26 August, 7:00 am – 7:30 pm CDT)[4]
  • Peramivir susceptibility of Influenza A and B Neuraminidase Variants Selected Under Pressure with Neuraminidase Inhibitors (Abstract # O-6, 25 August, 12:15 – 12:30 pm CDT)[7]

For a complete list of abstracts please visit: www.2016.isirv.org

Options IX is the largest international conference exclusively devoted to influenza prevention, control and treatment and is led by the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV).[8]

About Seasonal Influenza
Influenza is a common, highly contagious infectious disease that can cause severe illness and life-threatening complications in many people. Because transmission to others may occur one day before symptoms develop and up to five to seven days after becoming sick, the disease can be easily transmitted to others.[9] Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases death.[9] On average, more than 200,000 people are hospitalized due to influenza-related complications in the US each year.[10]

About Seqirus
Seqirus is the new global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccines business formerly owned by Novartis AG. As the second largest influenza vaccine provider in the world, Seqirus is driven by the promise it shares with parent company, CSL Limited, to provide medicines that help to protect and save lives.

Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally, with extensive research and production expertise and manufacturing plants in the US, Europe and Australia and a commercial presence in 20 countries.

Seqirus is part of CSL Limited (ASX:CSL), headquartered in Melbourne, Australia. The CSL Group of companies employs more than 16,000 people with operations in more than 30 countries.

For more information visit www.seqirus.com and www.csl.com.

References

1.       Leav B, et al. MF59® Adjuvanted Seasonal Trivalent Influenza Vaccine: Pooled Analysis of Safety in Older Adults ≥65 Years of Age. Presented at Options IX for the Control of Influenza Conference, Chicago, USA, 24-28 August 2016.

2.       Settembre, E., et al. Antibody Responses Against Antigenically Drifted Strains of FLUAD™, a Seasonal MF59® Adjuvanted Trivalent Influenza Vaccine in Older Adults. Presented at Options IX for the Control of Influenza Conference, Chicago, USA, 24-28 August 2016.

3.       Leong, J., et al. Randomized Trial to Compare Immunogenicity and Safety of Seqirus Quadrivalent Inactivated Influenza Vaccine with a US-Licensed Quadrivalent Influenza Vaccine in Children 5 to 17 Years of Age. Presented at Options IX for the Control of Influenza Conference, Chicago, USA, 24-28 August 2016.

4.       Albano, F. R., et al. Randomized Trial to Compare Immunogenicity and Safety of Seqirus Quadrivalent Inactivated Influenza Vaccine with Two Trivalent Influenza Vaccine Comparators in Adults Aged 18 Years and Above

5.       Hohenboken, M., et al. Heterologous Antibody Responses to MF59®-Adjuvanted A/H5N1 Pandemic Vaccine in Adults, Pediatric and Elderly Populations. Presented at Options IX for the Control of Influenza Conference, Chicago, USA, 24-28 August 2016.

6.       Petri, E. Health Economics for Seasonal Influenza Vaccination of Older Adults in Italy. Presented at Options IX for the Control of Influenza Conference, Chicago, USA, 24-28 August 2016.

7.       Tu, V., et al. Peramivir susceptibility of Influenza A and B Neuraminidase Variants Selected Under Pressure with Neuraminidase Inhibitors. Presented at Options IX for the Control of Influenza Conference, Chicago, USA, 24-28 August 2016.

8.       The International Society for Influenza and other Respiratory Virus Diseases (ISIRV). Options IX for the Control of Influenza Conference. Available at: https://www.isirv.org/site/.  Accessed August 2016.

9.       Centers for Disease Control and Prevention (CDC). Key Facts about Influenza (Flu) & Flu Vaccine. Updated 2015. Available at: http://www.cdc.gov/flu/keyfacts.htm.  Accessed August 2016.

10.    Thompson, W. W., et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333-1340.

Media Contact

Monica Galimberti        
Corporate Affairs, Seqirus
[email protected]
[email protected]
Phone: +39 335 7440521 (mobile)

SOURCE Seqirus

Related Links

http://www.seqirus.com

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.